Background: The study was conducted to compare the efficacy and acceptability of second-trimester induction termination using vaginal misoprostol to hypertonic saline and d-cloprostenol, a prostaglandin F(2alpha) (PGF) analogue, in Tashkent, Uzbekistan.
Study Design: Eleven clinics providing second-trimester induction terminations were randomized to provide one of two regimens for second-trimester induction termination: vaginal misoprostol 400 mcg every 3 h or hypertonic 10% saline intrauterine instillation plus an intravenous PGF analogue, d-cloprostenol, 2.5 mg/h. Demographic information, and obstetric and medical history data were collected, and interviewers administered questionnaires to measure procedural pain and satisfaction. Differences in procedure time and complication rate, the primary outcomes, were analyzed with survival analysis and chi(2) tests.
Results: Of 228 participants, 120 received misoprostol and 108 received hypertonic saline and d-cloprostenol; the groups did not significantly differ by age, parity or gestational age. Both misoprostol and saline procedures were effective, with 99.2% and 100% successful abortion rates, respectively. Median procedure time (13.1 vs. 29.2 h, p<.001), and number of women with retained placenta (2 vs. 70, p<.001) or hemorrhage (3 vs. 19, p=.001) were lower for the misoprostol group. Both provider (p<.001) and patient (p<.001) procedural satisfaction scores were higher for the misoprostol group.
Conclusion: While equally effective, vaginal misoprostol had a shorter time to abortion, was more acceptable to providers and patients and had fewer complications than saline instillation plus intravenous administration of a PGF analogue in Tashkent. This evidence supports change of the existing standard of care for second-trimester induction termination in Uzbekistan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2007.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comparative analysis of methods of preinduction cervical ripening and induction of labor in Poland and in Germany (Part II): maternal and neonatal outcomes.
BMC Pregnancy Childbirth
January 2025
Hochschule für Gesundheitsfachberufe in Eberswalde, Schicklerstraße 20, 16225, Eberswalde, Germany.
The benefits and risks of delivery should always be considered before initiating preinduction cervical ripening and labor induction. Understanding the benefits and potential complications is crucial for healthcare professionals to make informed decisions and provide optimal care. The research was conducted retrospectively between January 2019 and July 2022.
View Article and Find Full Text PDFProspective Comparative Study of Misoprostol Alone Versus Mifepristone Plus Misoprostol for Second-Trimester Pregnancy Termination.
J Obstet Gynaecol India
December 2024
DNB Resident, Department of Obstetrics and Gynaecology, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan India.
Introduction: MTP has been legalized in India through the Medical Termination of Pregnancy Act, of 1971, which allows pregnancy termination up to 20 weeks. The present study included second-trimester pregnancy terminations and the main aim of the study is to compare the efficacy and safety of tablet mifepristone 24 h before vaginal tablet misoprostol in group-I with vaginal tablet misoprostol alone in group-II as a method of second-trimester pregnancy termination.
Methodology: It was a prospective randomized comparative study conducted at the Department of Obstetrics and Gynaecology, R.
Uterine rupture with induction using misoprostol for intrauterine foetal death in the second trimester: A case report.
Case Rep Womens Health
December 2024
Médecins Sans Frontières-Belgique (OCB), Avenue 7 Février, Grande passe, Port-à-Piment, Haïti.
Uterine rupture is a well-known, life-threatening complication of misoprostol use; the incidence is remarkably low. Herein, we report what seems to be the first documented case of uterine rupture following induction of labour for intrauterine foetal death in the second trimester without a uterine scar. A 40-year-old woman with no history of caesarean section or uterine surgery presented with mild lower abdominal pain and mild genital bleeding.
View Article and Find Full Text PDFAre assisted reproductive technology pregnancies more likely to be exposed to teratogenic medication? A whole-population study.
Aust N Z J Obstet Gynaecol
December 2024
Telethon Kids Institute, Perth, Western Australia, Australia.
Background: Assisted reproductive technology (ART) pregnancies are at greater risk of birth defects than non-ART pregnancies. Teratogenic medication exposure is a potential cause of birth defects that has not been compared between ART and non-ART pregnancies.
Aims: To determine whether the prevalence of exposure to teratogenic medicines during pregnancy varies by conception method (ART and three non-ART groups: ovulation induction (OI), subfertile untreated, and fertile naturally conceiving).
Association of body mass index on time to fetal expulsion for individuals undergoing medication abortion over 13 weeks gestational duration.
Contraception
November 2024
Oregon Health & Science University, Department of Family Planning, Portland, OR, USA.
Objectives: This study aimed to examine the association of body mass index (BMI, kg/m) with time to fetal expulsion for individuals undergoing medication abortion over 13 weeks.
Study Design: This is a retrospective cohort study of singleton pregnancies undergoing medication abortion >13 weeks at a single academic medical center between 2020 and 2024. Our primary outcome was time to fetal expulsion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!